Jpmorgan Chase & CO Citius Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 51,224 shares of CTXR stock, worth $34,832. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,224
Previous 79,745
35.77%
Holding current value
$34,832
Previous $60,000
23.33%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CTXR
# of Institutions
73Shares Held
26.8MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY8.73MShares$5.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.01MShares$4.76 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.95MShares$2 Million0.0% of portfolio
-
State Street Corp Boston, MA2.21MShares$1.5 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.12MShares$761,7960.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $99.4M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...